Symbols / ABSI
ABSI Chart
About
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 407.51M |
| Enterprise Value | 261.25M | Income | -114.60M | Sales | 2.81M |
| Book/sh | 1.41 | Cash/sh | 1.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 156 | IPO | — |
| P/E | — | Forward P/E | -3.84 | PEG | — |
| P/S | 144.76 | P/B | 1.93 | P/C | — |
| EV/EBITDA | -2.48 | EV/Sales | 92.81 | Quick Ratio | 5.17 |
| Current Ratio | 5.89 | Debt/Eq | 2.96 | LT Debt/Eq | — |
| EPS (ttm) | -0.91 | EPS next Y | -0.70 | EPS Growth | — |
| Revenue Growth | -77.80% | Earnings | 2026-03-24 | ROA | -30.62% |
| ROE | -55.68% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -79.77% | Profit Margin | 0.00% | Shs Outstand | 150.37M |
| Shs Float | 126.93M | Short Float | 29.13% | Short Ratio | 10.33 |
| Short Interest | — | 52W High | 5.23 | 52W Low | 2.01 |
| Beta | 2.12 | Avg Volume | 3.54M | Volume | 2.07M |
| Target Price | $8.05 | Recom | None | Prev Close | $2.65 |
| Price | $2.71 | Change | 2.26% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.05
Mean price target
2. Current target
$2.71
Latest analyst target
3. DCF / Fair value
$-4.56
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.71
Low
$4.32
High
$10.00
Mean
$8.05
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-18 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-12-12 | reit | Needham | Buy → Buy | $7 |
| 2025-11-13 | main | Needham | Buy → Buy | $7 |
| 2025-10-02 | init | JP Morgan | — → Overweight | — |
| 2025-08-18 | main | Morgan Stanley | Overweight → Overweight | $6 |
| 2025-08-13 | main | Needham | Buy → Buy | $8 |
| 2025-07-28 | main | Morgan Stanley | Overweight → Overweight | $6 |
| 2025-05-14 | reit | Needham | Buy → Buy | $9 |
| 2025-04-16 | main | Keybanc | Overweight → Overweight | $9 |
| 2025-04-09 | reit | Needham | Buy → Buy | $9 |
| 2025-03-20 | reit | Guggenheim | Buy → Buy | $10 |
| 2025-03-19 | reit | Needham | Buy → Buy | $9 |
| 2025-03-19 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-01-22 | init | Needham | — → Buy | $9 |
| 2025-01-17 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-01-10 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-01-08 | main | Keybanc | Overweight → Overweight | $5 |
| 2025-01-08 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-12-13 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-12-03 | reit | Guggenheim | Buy → Buy | $10 |
- AI drug developer Absci to reveal 2025 results in March webcast - Stock Titan ue, 24 Feb 2026 13
- Absci Corporation's (NASDAQ:ABSI) recent 12% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance Wed, 21 Jan 2026 08
- Absci Corporation (NASDAQ:ABSI) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat Sat, 21 Feb 2026 06
- $ABSI stock is down 8% today. Here's what we see in our data. - Quiver Quantitative Mon, 03 Nov 2025 08
- Insiders Who Purchased US$582.6k Of Absci Stock May Not Have Expected 17% Tumble - simplywall.st Fri, 06 Feb 2026 08
- Absci stock price target raised to $9 from $8 at Jones Trading - Investing.com Fri, 28 Nov 2025 08
- AI-driven drug developer Absci lines up four March investor events - Stock Titan ue, 17 Feb 2026 13
- Analysts Cut Absci (ABSI) Target, Spotlight New Alopecia Therapy in Early Trials - Yahoo Finance Wed, 14 Jan 2026 08
- Insider Purchase: Director at $ABSI Buys 40,000 Shares | ABSI Stock News - Quiver Quantitative ue, 09 Dec 2025 08
- Insider Selling: Absci (NASDAQ:ABSI) CEO Sells 26,761 Shares of Stock - MarketBeat Wed, 04 Feb 2026 08
- ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study - Yahoo Finance Fri, 05 Dec 2025 08
- $ABSI stock is up 19% today. Here's what we see in our data. - Quiver Quantitative Wed, 15 Oct 2025 07
- Absci Corporation (ABSI) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance Wed, 12 Nov 2025 08
- $ABSI stock is down 21% today. Here's what we see in our data. - Quiver Quantitative hu, 13 Nov 2025 08
- $ABSI stock is up 14% today. Here's what we see in our data. - Quiver Quantitative hu, 04 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 26761 | 80015 | — | Sale at price 2.99 per share. | MCCLAIN SEAN | Chief Executive Officer | — | 2026-02-02 00:00:00 | D |
| 1 | 17496 | 52313 | — | Sale at price 2.99 per share. | JONASSON ZACHARIAH | Chairman of the Board | — | 2026-02-02 00:00:00 | D |
| 2 | 15000 | — | — | Stock Award(Grant) at price 0.00 per share. | BEDRICK TODD | Officer | — | 2026-01-28 00:00:00 | D |
| 3 | 40000 | 148800 | — | Purchase at price 3.72 per share. | VAN HOUTEN FRANS | Director | — | 2025-12-05 00:00:00 | D |
| 4 | 10000 | 27000 | — | Purchase at price 2.70 per share. | BEDRICK TODD | Officer | — | 2025-09-22 00:00:00 | D |
| 5 | 95785 | 254788 | — | Purchase at price 2.66 per share. | PANGALOS MENELAS N | Director | — | 2025-09-22 00:00:00 | D |
| 6 | 50000 | 152000 | — | Purchase at price 3.04 per share. | BUSCH ANDREAS | Officer | — | 2025-07-28 00:00:00 | D |
| 7 | 14500 | — | — | Stock Award(Grant) at price 0.00 per share. | RABINOVITSJ DANIEL A | Director | — | 2025-06-11 00:00:00 | D |
| 8 | 14500 | — | — | Stock Award(Grant) at price 0.00 per share. | VAN HOUTEN FRANS | Director | — | 2025-06-11 00:00:00 | D |
| 9 | 14500 | — | — | Stock Award(Grant) at price 0.00 per share. | PANGALOS MENELAS N | Director | — | 2025-06-11 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -4.48M | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.08 |
| NormalizedEBITDA | -89.08M | -74.12M | -91.29M | -99.77M |
| TotalUnusualItems | 0.00 | -21.34M | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -21.34M | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -103.11M | -110.57M | -104.90M | -100.96M |
| ReconciledDepreciation | 13.39M | 14.00M | 13.10M | 6.65M |
| EBITDA | -89.08M | -95.46M | -91.29M | -99.77M |
| EBIT | -102.47M | -109.46M | -104.39M | -106.43M |
| NetInterestIncome | -565.00K | -1.01M | -972.00K | -3.43M |
| InterestExpense | 565.00K | 1.01M | 972.00K | 3.43M |
| NormalizedIncome | -103.11M | -93.71M | -104.90M | -100.96M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -103.11M | -110.57M | -104.90M | -100.96M |
| TotalExpenses | 113.42M | 99.90M | 112.50M | 80.02M |
| TotalOperatingIncomeAsReported | -108.89M | -115.52M | -106.75M | -75.24M |
| DilutedAverageShares | 110.24M | 92.03M | 90.85M | 49.69M |
| BasicAverageShares | 110.24M | 92.03M | 90.85M | 49.69M |
| DilutedEPS | -0.94 | -1.20 | -1.15 | -2.08 |
| BasicEPS | -0.94 | -1.20 | -1.15 | -2.08 |
| DilutedNIAvailtoComStockholders | -103.11M | -110.57M | -104.90M | -103.24M |
| NetIncomeCommonStockholders | -103.11M | -110.57M | -104.90M | -103.24M |
| OtherunderPreferredStockDividend | 0.00 | |||
| PreferredStockDividends | 2.28M | |||
| NetIncome | -103.11M | -110.57M | -104.90M | -100.96M |
| NetIncomeIncludingNoncontrollingInterests | -103.11M | -110.57M | -104.90M | -100.96M |
| NetIncomeContinuousOperations | -103.11M | -110.57M | -104.90M | -100.96M |
| TaxProvision | 70.00K | 100.00K | -461.00K | -8.90M |
| PretaxIncome | -103.04M | -110.47M | -105.36M | -109.86M |
| OtherIncomeExpense | 6.42M | -15.28M | 2.36M | -31.19M |
| OtherNonOperatingIncomeExpenses | 6.42M | 6.06M | 2.36M | -31.19M |
| SpecialIncomeCharges | 0.00 | -21.34M | 0.00 | |
| ImpairmentOfCapitalAssets | 0.00 | 21.34M | 0.00 | |
| NetNonOperatingInterestIncomeExpense | -565.00K | -1.01M | -972.00K | -3.43M |
| InterestExpenseNonOperating | 565.00K | 1.01M | 972.00K | 3.43M |
| OperatingIncome | -108.89M | -94.18M | -106.75M | -75.24M |
| OperatingExpense | 113.42M | 99.90M | 112.50M | 80.02M |
| DepreciationAmortizationDepletionIncomeStatement | 13.39M | 14.00M | 13.04M | 6.65M |
| DepreciationAndAmortizationInIncomeStatement | 13.39M | 14.00M | 13.04M | 6.65M |
| ResearchAndDevelopment | 63.86M | 48.07M | 58.91M | 44.59M |
| SellingGeneralAndAdministration | 36.17M | 37.83M | 40.55M | 28.78M |
| TotalRevenue | 4.53M | 5.72M | 5.75M | 4.78M |
| OperatingRevenue | 4.53M | 5.72M | 5.75M | 4.78M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 115.36M | 93.09M | 92.41M | 92.65M |
| ShareIssued | 115.36M | 93.09M | 92.41M | 92.65M |
| TotalDebt | 10.11M | 15.88M | 22.98M | 20.01M |
| TangibleBookValue | 134.25M | 127.92M | 201.46M | 289.78M |
| InvestedCapital | 183.12M | 184.09M | 285.34M | 369.63M |
| WorkingCapital | 105.17M | 91.02M | 156.59M | 239.22M |
| NetTangibleAssets | 134.25M | 127.92M | 201.46M | 289.78M |
| CapitalLeaseObligations | 6.12M | 7.96M | 12.05M | 16.49M |
| CommonStockEquity | 179.13M | 176.18M | 274.41M | 366.11M |
| TotalCapitalization | 180.39M | 180.84M | 282.40M | 367.23M |
| TotalEquityGrossMinorityInterest | 179.13M | 176.18M | 274.41M | 366.11M |
| StockholdersEquity | 179.13M | 176.18M | 274.41M | 366.11M |
| GainsLossesNotAffectingRetainedEarnings | -4.00K | -37.00K | -120.00K | -13.00K |
| OtherEquityAdjustments | -4.00K | -37.00K | -120.00K | -13.00K |
| RetainedEarnings | -509.60M | -406.50M | -295.93M | -191.03M |
| AdditionalPaidInCapital | 688.73M | 582.70M | 570.45M | 557.14M |
| CapitalStock | 12.00K | 9.00K | 9.00K | 9.00K |
| CommonStock | 12.00K | 9.00K | 9.00K | 9.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 34.48M | 41.12M | 46.59M | 60.09M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 5.82M | 11.56M | 16.32M | 26.23M |
| OtherNonCurrentLiabilities | 133.00K | 295.00K | 35.00K | 12.16M |
| NonCurrentDeferredLiabilities | 0.00 | 966.00K | 238.00K | 743.00K |
| NonCurrentDeferredRevenue | 0.00 | 966.00K | 0.00 | |
| NonCurrentDeferredTaxesLiabilities | 186.00K | 238.00K | 743.00K | |
| LongTermDebtAndCapitalLeaseObligation | 5.69M | 10.30M | 16.05M | 13.32M |
| LongTermCapitalLeaseObligation | 4.43M | 5.64M | 8.07M | 12.20M |
| LongTermDebt | 1.26M | 4.66M | 7.98M | 1.12M |
| CurrentLiabilities | 28.66M | 29.56M | 30.27M | 33.86M |
| OtherCurrentLiabilities | 12.75M | 12.75M | ||
| CurrentDeferredLiabilities | 1.12M | 3.17M | 445.00K | 1.35M |
| CurrentDeferredRevenue | 1.12M | 3.17M | 445.00K | 1.35M |
| CurrentDebtAndCapitalLeaseObligation | 4.42M | 5.58M | 6.93M | 6.69M |
| CurrentCapitalLeaseObligation | 1.69M | 2.32M | 3.99M | 4.29M |
| CurrentDebt | 2.73M | 3.26M | 2.95M | 2.40M |
| OtherCurrentBorrowings | 2.73M | 3.26M | 2.95M | 2.40M |
| PayablesAndAccruedExpenses | 10.37M | 8.06M | 22.89M | 25.82M |
| CurrentAccruedExpenses | 6.84M | 6.55M | 20.48M | 17.43M |
| Payables | 3.53M | 1.50M | 2.41M | 8.38M |
| AccountsPayable | 3.53M | 1.50M | 2.41M | 8.38M |
| TotalAssets | 213.61M | 217.30M | 321.01M | 426.19M |
| TotalNonCurrentAssets | 79.78M | 96.72M | 134.15M | 153.12M |
| OtherNonCurrentAssets | 1.76M | 2.65M | 3.15M | 18.14M |
| GoodwillAndOtherIntangibleAssets | 44.88M | 48.25M | 72.96M | 76.33M |
| OtherIntangibleAssets | 44.88M | 48.25M | 51.62M | 54.99M |
| Goodwill | 0.00 | 21.34M | 21.34M | |
| NetPPE | 33.13M | 45.82M | 58.04M | 58.65M |
| AccumulatedDepreciation | -31.57M | -23.99M | -15.20M | -6.38M |
| GrossPPE | 64.70M | 69.81M | 73.25M | 65.03M |
| Leases | 27.06M | 27.05M | 26.86M | 24.67M |
| ConstructionInProgress | 0.00 | 293.00K | 933.00K | |
| OtherProperties | 31.26M | 36.59M | 39.49M | 34.31M |
| MachineryFurnitureEquipment | 6.38M | 6.17M | 6.61M | 5.12M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 133.83M | 120.58M | 186.86M | 273.08M |
| OtherCurrentAssets | 5.46M | 4.54M | 5.86M | 8.57M |
| RestrictedCash | 15.95M | 16.19M | 15.02M | 10.51M |
| PrepaidAssets | 8.57M | |||
| Receivables | 0.00 | 2.19M | 1.55M | 1.43M |
| OtherReceivables | 2.19M | 1.55M | 1.43M | |
| AccountsReceivable | 0.00 | 2.19M | ||
| CashCashEquivalentsAndShortTermInvestments | 112.42M | 97.66M | 164.43M | 252.57M |
| OtherShortTermInvestments | 71.21M | 25.30M | 104.48M | 0.00 |
| CashAndCashEquivalents | 41.21M | 72.36M | 59.95M | 252.57M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -72.81M | -65.50M | -97.51M | -98.64M |
| RepaymentOfDebt | -4.03M | -5.34M | -7.45M | -4.15M |
| IssuanceOfDebt | 0.00 | 12.03M | 125.00M | |
| IssuanceOfCapitalStock | 86.56M | 862.00K | 656.00K | 215.34M |
| CapitalExpenditure | -404.00K | -860.00K | -16.18M | -38.05M |
| InterestPaidSupplementalData | 561.00K | 970.00K | 895.00K | 652.00K |
| EndCashPosition | 58.21M | 89.67M | 76.84M | 279.93M |
| BeginningCashPosition | 89.67M | 76.84M | 279.93M | 71.71M |
| ChangesInCash | -31.45M | 12.82M | -203.08M | 208.22M |
| FinancingCashFlow | 82.53M | -4.48M | 5.24M | 336.19M |
| CashFlowFromContinuingFinancingActivities | 82.53M | -4.48M | 5.24M | 336.19M |
| NetPreferredStockIssuance | 0.00 | 4.94M | ||
| PreferredStockIssuance | 0.00 | 4.94M | ||
| NetCommonStockIssuance | 86.56M | 862.00K | 656.00K | 210.40M |
| CommonStockIssuance | 86.56M | 862.00K | 656.00K | 210.40M |
| NetIssuancePaymentsOfDebt | -4.03M | -5.34M | 4.58M | 120.85M |
| NetLongTermDebtIssuance | -4.03M | -5.34M | 4.58M | 120.85M |
| LongTermDebtPayments | -4.03M | -5.34M | -7.45M | -4.15M |
| LongTermDebtIssuance | 0.00 | 12.03M | 125.00M | |
| InvestingCashFlow | -41.58M | 81.94M | -126.98M | -67.38M |
| CashFlowFromContinuingInvestingActivities | -41.58M | 81.94M | -126.98M | -67.38M |
| NetOtherInvestingChanges | 650.00K | |||
| NetInvestmentPurchaseAndSale | -42.11M | 82.55M | -103.59M | -1.20M |
| SaleOfInvestment | 144.00M | 229.90M | 5.00M | 0.00 |
| PurchaseOfInvestment | -186.11M | -147.35M | -108.59M | -1.20M |
| NetBusinessPurchaseAndSale | 0.00 | -8.00M | -28.13M | |
| PurchaseOfBusiness | 0.00 | -8.00M | -28.13M | |
| NetPPEPurchaseAndSale | 535.00K | -606.00K | -16.04M | -38.05M |
| SaleOfPPE | 939.00K | 254.00K | 133.00K | 0.00 |
| PurchaseOfPPE | -404.00K | -860.00K | -16.18M | -38.05M |
| OperatingCashFlow | -72.40M | -64.64M | -81.34M | -60.60M |
| CashFlowFromContinuingOperatingActivities | -72.40M | -64.64M | -81.28M | -60.60M |
| ChangeInWorkingCapital | -368.00K | 1.52M | -1.54M | -3.15M |
| ChangeInOtherWorkingCapital | -3.79M | 2.84M | -1.55M | 1.98M |
| ChangeInOtherCurrentAssets | -68.00K | -255.00K | 13.00K | 126.00K |
| ChangeInPayablesAndAccruedExpense | 1.73M | -2.00M | -2.24M | 2.15M |
| ChangeInAccruedExpense | -295.00K | -1.21M | -1.71M | 581.00K |
| ChangeInPayable | 2.03M | -786.00K | -533.00K | 1.57M |
| ChangeInAccountPayable | 2.03M | -786.00K | -533.00K | 1.57M |
| ChangeInPrepaidAssets | -484.00K | 1.60M | 2.38M | -7.64M |
| ChangeInReceivables | 2.24M | -666.00K | -148.00K | 230.00K |
| ChangesInAccountReceivables | 2.24M | -666.00K | ||
| OtherNonCashItems | 1.97M | 334.00K | 658.00K | 31.02M |
| StockBasedCompensation | 19.45M | 11.42M | 12.54M | 10.61M |
| AssetImpairmentCharge | 0.00 | 21.34M | 0.00 | |
| AmortizationOfSecurities | -3.74M | -2.67M | -688.00K | 0.00 |
| DeferredTax | -52.00K | -505.00K | -8.90M | |
| DeferredIncomeTax | -52.00K | -505.00K | -8.90M | |
| DepreciationAmortizationDepletion | 13.39M | 14.00M | 13.10M | 6.65M |
| DepreciationAndAmortization | 13.39M | 14.00M | 13.10M | 6.65M |
| AmortizationCashFlow | 3.40M | 3.40M | ||
| AmortizationOfIntangibles | 3.40M | 3.40M | ||
| Depreciation | 10.60M | 9.70M | ||
| OperatingGainsLosses | 4.12M | |||
| GainLossOnInvestmentSecurities | 4.12M | |||
| NetForeignCurrencyExchangeGainLoss | -11.00K | |||
| NetIncomeFromContinuingOperations | -103.11M | -110.57M | -104.90M | -100.96M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ABSI
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|